V. I. Sergeeva

V. I. Sergeeva

Auto-generated profile, based on publicly available information

V. I. Sergeeva

National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2026 in Tuberculosis and Lung Diseases
Verified
Journal Article
Closed access
MRM. I. Romanov
M. I. Romanov
AGA. I. Gayda
A. I. Gayda
ТТТатьяна Тюлькова
Татьяна Тюлькова
VSV. I. Sergeeva
V. I. Sergeeva
Irina M. Le-DeygenIrina M. Le-Deygen
Irina M. Le-Deygen
ASA. G. Samoylova
A. G. Samoylova
50 scientific publications between 2018 and 2025 were analyzed, focusing on drug delivery systems and benefits of linezolid-loaded nanoparticles. Orally administered anti-tuberculosis drugs do not always achieve sufficient bactericidal concentrations at the site of infection, regardless of their serum levels. Consequently, even with treatment adherence, approximately 1% of patients may develop multidrug-resistant tuberculosis (MDR-TB) due to pharmacokinetic variability. This highlights the need for advanced delivery systems that ensure targeted drug release directly into the affected lung tissue. Nanoformulations of linezolid (e.g., dry powders, aerosols) have been developed. These formulations remain stable for up to 6 months and increase bioavailability to 55.2%, enabling dose reduction. This opens up real prospects for lowering the therapeutic dose of the drug.